Larbex Steri-Neb

Budesonide, the active ingredient in Larbex Steri-Neb, is a glucocorticoid corticosteroid presented as a nebulizer solution for inhalation use. It treats airway inflammation in asthma and chronic obstructive pulmonary disease, improving breathing and reducing exacerbations in both adult and pediatric patients as prescribed.

GNH USA supplies Larbex Steri-Neb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global demand across multiple regions and markets.

Budesonide is an inhaled glucocorticoid that reduces airway inflammation in chronic respiratory diseases.

Asthma: Reduces airway inflammation, improves bronchial tone, and decreases the frequency and severity of asthma attacks, leading to better symptom control and fewer rescue medication requirements.

Chronic obstructive pulmonary disease (COPD): Diminishes inflammatory cell infiltration in the airways, helps prevent exacerbations, improves spirometric measures such as FEV1, and supports overall respiratory function in stable COPD patients.

Inhaled budesonide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Oral thrush (candidiasis): fungal infection of the mouth. - Hoarseness or voice change: irritation of the laryngeal mucosa. - Cough or throat irritation: local discomfort after inhalation. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Pneumonia: especially in patients with COPD. - Paradoxical bronchospasm: sudden worsening of airway obstruction. - Severe hypokalemia: low blood potassium levels. - Immunosuppression leading to increased infection risk. - Ocular effects such as cataract formation or glaucoma with long‑term use.

Before initiating therapy, clinicians should consider several safety measures.

- Assess infection risk: evaluate for active respiratory infections before starting treatment. - Monitor lung function: perform regular spirometry to gauge response and adjust therapy. - Screen for tuberculosis: consider latent TB testing in high‑risk patients. - Use mouth rinse: advise patients to rinse the mouth after inhalation to reduce local candidiasis. - Avoid abrupt discontinuation: taper the dose when stopping long‑term therapy to prevent adrenal insufficiency. - Store at room temperature: keep the nebulizer solution in the original container, protect from moisture and light.

Budesonide may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic budesonide exposure. - Systemic immunosuppressants (e.g., ritonavir): additive immunosuppression risk. - Live vaccines: reduced vaccine efficacy and possible infection.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may modestly raise budesonide levels. - Diuretics (e.g., furosemide): can exacerbate hypokalemia when combined with systemic steroids. - Antifungal azoles (e.g., voriconazole): may increase plasma concentrations of budesonide.